Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023)
Genelux (GNLX) posted quarterly Total Non-Current Liabilities of $1.9 million for Q4 2023, down 80.74% year-over-year from $9.7 million in Q4 2022, and up 44.76% quarter-over-quarter from $1.3 million in Q3 2023.
Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Genelux's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.9 million for Q4 2023.
- In Q4 2023, Total Non-Current Liabilities fell 80.74% year-over-year to $1.9 million; the TTM figure through Dec 2023 stood at $1.9 million (down 80.74% YoY), while the FY2023 annual figure was $1.9 million, down 80.74% from the prior year.
- Total Non-Current Liabilities for Q4 2023 stood at $1.9 million, up from $1.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.7 million in Q4 2022, with the low at $1.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Dec 31, 2022 | 9.69 Mn |